Format

Send to

Choose Destination
Expert Rev Vaccines. 2015 Apr;14(4):489-92. doi: 10.1586/14760584.2015.1011135. Epub 2015 Feb 6.

IL-33 isoforms: their future as vaccine adjuvants?

Author information

1
Department of Pathology, University of Pennsylvania, 505A Stellar-Chance Laboratories, 422 Curie Blvd, Philadelphia, PA 19104, USA.

Abstract

The identification and characterization of cytokine isoforms is likely to provide critical important new insight into immunobiology. Cytokine isoforms can provide additional diversity to their complex biological effects that participate in control and protection against different foreign pathogens. Recently, IL-33 has been identified as a proinflammatory cytokine having several different biologically active isoform products. Originally associated with Th2 immunity, new evidence now supports the role of two IL-33 isoforms to facilitate the generation of protective Th1 and CD8 T cell immunity against specific pathogens. Therefore, a better understanding of the IL-33 isoforms will inform us on how to utilize them to facilitate their development as tools as vaccine adjuvants for immune therapy.

KEYWORDS:

CD8 T cell; DNA vaccine; IL 33; adjuvant; cancer vaccine; cytokine; immunotherapies; isoform

PMID:
25656504
PMCID:
PMC4573560
DOI:
10.1586/14760584.2015.1011135
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center